Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer

BACKGROUND: Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have become the gold standard for EGFR‐mutated non‐small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed for the treatment of several malignancies, including lung cancer. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Takashi, Nagashima, Hiromi, Akiyama, Masachika, Utsumi, Yu, Sato, Hideomi, Chiba, Shinji, Sugai, Mayu, Ube, Kenji, Mori, Yoshiaki, Watanabe, Kana, Fukuhara, Tatsuro, Maemondo, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807326/
https://www.ncbi.nlm.nih.gov/pubmed/34904383
http://dx.doi.org/10.1111/1759-7714.14267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807326/
https://www.ncbi.nlm.nih.gov/pubmed/34904383
http://dx.doi.org/10.1111/1759-7714.14267

Ejemplares similares